Want to see HK:2179 full AI Analyst Report?
Top Page
Jiangsu Recbio Technology Co., Ltd. Class H
(2179)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$4.50
▲(7.66% Upside)
Action:Reiterated
Date:08/10/26
The score is primarily weighed down by weak financial performance—volatile revenue, sustained heavy losses, and ongoing cash burn—despite improved leverage. Technicals are neutral with only modest positive momentum, and valuation remains constrained by negative earnings and no stated dividend support.
Positive Factors
Improved Leverage
The reduction in debt-to-equity improves financial flexibility and lowers balance-sheet risk relative to the prior year. Although leverage remains meaningful, a stronger capital structure can better support development spending and reduce pressure from financing obligations over the next several quarters.
Negative Factors
Sharp Revenue Decline
A steep annual revenue decline and continued volatility indicate that commercialization has not yet produced a stable revenue base. Uneven sales reduce earnings visibility, make operating expenses harder to absorb and increase dependence on successful future product launches or other funding sources.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Leverage
The reduction in debt-to-equity improves financial flexibility and lowers balance-sheet risk relative to the prior year. Although leverage remains meaningful, a stronger capital structure can better support development spending and reduce pressure from financing obligations over the next several quarters.
Read all positive factors
Jiangsu Recbio Technology Co., Ltd. Class H (2179) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.74B
Dividend YieldN/A
Average Volume (3M)650.00
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue Growth-82.46%
EPS Growth41.19%
CountryHK
Employees491
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.77
Shares Outstanding458,092,160
10 Day Avg. Volume1,300
30 Day Avg. Volume650
Financial Highlights & Ratios
PEG Ratio0.93
Price to Book (P/B)2.70
Price to Sales (P/S)153.96
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.93
Revenue Forecast (FY)HK$11.00M
Jiangsu Recbio Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portio...
How the Company Makes Money
The company makes money primarily through (1) commercialization of its vaccine/biologics products (when approved), generating revenue from product sales to customers in the healthcare supply chain; and (2) out-licensing and/or collaboration arrang...
Jiangsu Recbio Technology Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.29M | 12.40M | 27.00M | 30.38M | 5.33M | 6.20M |
| Gross Profit | -47.33M | -91.46M | 15.95M | 22.34M | 5.33M | 6.20M |
| EBITDA | -357.03M | -483.72M | -491.04M | -553.85M | -834.14M | -590.00M |
| Net Income | -477.06M | -594.59M | -562.39M | -571.96M | -719.20M | -657.56M |
Balance Sheet | ||||||
| Total Assets | 1.60B | 1.76B | 1.94B | 2.19B | 2.31B | 1.92B |
| Cash, Cash Equivalents and Short-Term Investments | 187.51M | 351.99M | 448.31M | 837.76M | 1.33B | 1.18B |
| Total Debt | 672.99M | 638.75M | 889.10M | 650.79M | 282.63M | 76.72M |
| Total Liabilities | 1.10B | 1.06B | 1.41B | 1.12B | 656.53M | 245.92M |
| Stockholders Equity | 497.98M | 706.14M | 529.32M | 1.07B | 1.66B | 1.67B |
Cash Flow | ||||||
| Free Cash Flow | -505.26M | -601.50M | -636.66M | -862.18M | -888.04M | -710.79M |
| Operating Cash Flow | -445.83M | -502.64M | -464.82M | -638.07M | -579.54M | -472.92M |
| Investing Cash Flow | -78.43M | 35.43M | -279.04M | 9.42M | -378.43M | 68.70M |
| Financing Cash Flow | 596.88M | 499.77M | 218.06M | 275.27M | 839.44M | 1.23B |
Jiangsu Recbio Technology Co., Ltd. Class H Technical Analysis
Negative
4.18
Price Trends
4.86
Negative
4.88
Negative
4.83
Negative
Market Momentum
-0.15
Positive
9.64
Positive
43.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2179, the sentiment is Negative. The current price of 4.18 is below the 20-day moving average (MA) of 4.64, below the 50-day MA of 4.86, and below the 200-day MA of 4.83, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 9.64 is Positive, neither overbought nor oversold. The STOCH value of 43.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2179.
Jiangsu Recbio Technology Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$32.28B | 30.61 | 20.41% | ― | 32.63% | 8.74% | |
59 Neutral | HK$3.42B | 4.63 | 10.99% | ― | 1417.68% | 660.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$2.44B | 2.39 | -64.89% | ― | -99.15% | ― | |
49 Neutral | HK$2.90B | -14.35 | -26.14% | ― | -51.10% | -2384.76% | |
47 Neutral | HK$2.74B | -4.89 | -79.24% | ― | -82.46% | 41.19% | |
44 Neutral | HK$36.73B | -83.16 | -7.32% | ― | 34.83% | 58.94% |
* Healthcare Sector Average
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
4.42
-2.43
-35.55%
HK:6998
Genor Biopharma Holdings Limited
1.70
-2.37
-58.23%
HK:1875
TOT BIOPHARM International Co. Ltd.
3.58
1.40
64.22%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.46
-12.24
-41.21%
HK:2197
Clover Biopharmaceuticals Ltd.
1.79
-0.73
-28.97%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
50.65
-25.10
-33.14%
Jiangsu Recbio Technology Co., Ltd. Class H Corporate Events
Jiangsu Recbio Announces Board-Level Resignation and New Authorised Representative
Aug 25, 2026
Jiangsu Recbio Technology Co., Ltd. announced that executive director and board secretary Mr. Wei Qifang has resigned from his roles, including authorised representative and joint company secretary, effective August 25, 2026, citing personal reaso...
Jiangsu Recbio Sets Out Board Composition and Committee Structure
Aug 25, 2026
Jiangsu Recbio Technology Co., Ltd., a Hong Kong-listed joint stock company based in Jiangsu Province, has detailed the composition of its board of directors, which includes a non-executive chairman, two executive directors, several non-executive ...
Jiangsu Recbio Clarifies Board Composition and Committee Leadership
Aug 19, 2026
Jiangsu Recbio Technology Co., Ltd., a joint stock biopharmaceutical company based in Jiangsu Province and listed in Hong Kong as a Class H issuer, operates with a multi-tier board comprising executive, non-executive and independent non-executive ...
Recbio Advances Shingles and HPV Vaccines as Interim Loss Narrows
Aug 19, 2026
Jiangsu Recbio Technology Co., Ltd. reported significant RD progress in the first half of 2026, led by its novel adjuvanted recombinant shingles vaccine REC610, which has completed Phase III enrollment and dosing in China and advanced to the marke...
Jiangsu Recbio Formalizes H Share Full Circulation with Amended Articles
Aug 17, 2026
Jiangsu Recbio Technology Co., Ltd. has amended its Articles of Association following the completion of its H Share Full Circulation plan, which converted 141,953,489 previously unlisted shares into H shares. As a result, the company now reports a...
Jiangsu Recbio Sets Board Meeting to Review 2026 Interim Results and Consider Dividend
Aug 7, 2026
Jiangsu Recbio Technology Co., Ltd., a Hong Kong–listed biopharmaceutical company incorporated in the PRC, has a board structure that includes a non-executive chairman, multiple executive and non-executive directors, and several independent ...
Jiangsu Recbio Flags Narrowed First-Half Loss as Clinical Spend Eases
Jul 31, 2026
Jiangsu Recbio Technology has warned of a continued loss for the first half of 2026, although its estimated net loss has narrowed significantly compared with a year earlier. The improvement reflects the completion of heavy clinical trial investmen...
Recbio Reports Shingles Vaccine Milestone and Delay in HPV Filing
Jul 23, 2026
Jiangsu Recbio Technology Co., Ltd., a Hong Kong-listed Chinese vaccine developer, focuses on recombinant and adjuvanted vaccines targeting shingles and HPV, using advanced biotechnological platforms in its RD and manufacturing operations. Its pip...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.